Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
MaxCyte Inc on Monday said it signed a strategic platform licence with Vittoria Biotherapeutics to advance cellular therapies.
The cell-engineering technology platform based in Maryland, US said under the terms of the agreement, Vittoria will obtain non-exclusive clinical and commercial rights to use MaxCyte’s Flow Electroporation technology and ExPERT platform. Meanwhile, MaxCyte will have access to platform licensing fees and program-related revenue.
Vittoria Therapeutics is a gene-edited therapeutics company specialising in platform technologies for cellular therapies.
MaxCyte Chief Executive Officer Doug Doerfler said: ‘Through our partnership with Vittoria, MaxCyte has gained an opportunity to further validate and showcase our technology in a real-world setting and expand its footprint in the promising field of CAR-T therapies. We look forward to supporting Vittoria’s efforts to improve efficacy and enhance safety of T-cell therapies.’
Shares in MaxCyte were up 0.9% at 353.00 pence each in London on Monday afternoon.
Copyright 2023 Alliance News Ltd. All Rights Reserved.